Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma
- PMID: 38402310
- PMCID: PMC10894194
- DOI: 10.1038/s41598-024-55287-z
Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma
Erratum in
-
Author Correction: Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma.Sci Rep. 2024 May 30;14(1):12457. doi: 10.1038/s41598-024-63374-4. Sci Rep. 2024. PMID: 38816485 Free PMC article. No abstract available.
Abstract
This paper evaluates the effectiveness and safety of XEN63 stent, either standalone or in combination with phacoemulsification, in patients with primary open-angle glaucoma (POAG). Eighty eyes from 80 patients with medically uncontrolled POAG were assigned to undergo XEN63 implant. The primary outcome was the surgical success, defined as an intraocular pressure (IOP) lowering from preoperative values ≥ 20% and an IOP absolute value between 6 and 18 mmHg, with or without antiglaucoma medications. Forty-three (53.7%) eyes underwent XEN63-standalone and 37(46.2%) eyes a XEN63 + Phacoemulsification procedure. Success rate was 68.8% (55/80) eyes in the overall study sample, 69.8% (30/43) eyes in the XEN63-standalone group; and 67.6% (25/37) eyes in the XEN63 + Phaco group (p = 0.6133). Preoperative IOP was significantly lowered from 22.1 ± 4.9 mmHg and 19.8 ± 3.7 mmHg to 14.7 ± 5.3 mmHg and 13.8 ± 3.4 mmHg in the XEN63-standalone and XEN63 + Phaco groups, respectively (p < 0.0001 each, respectively); without significant differences between them at any of the time-points measured. Preoperative number of ocular-hypotensive drugs was significantly reduced from 2.3 ± 0.8 to 0.3 ± 0.7 drugs, from 2.5 ± 0.7 to 0.3 ± 0.7 drugs; and from 2.0 ± 0.8 to 0.3 ± 0.7 drugs, in the overall, XEN63-standalone, and XEN63 + Phaco groups, respectively. Regarding safety, 3(42.5%) eyes had transient hypotony at some point during the study, although only in one (1.2%) eye was clinically significant. Four (5.0%) eyes underwent a needling, 4 (5.0%) eyes underwent surgical-bleb-revision, 1 (1.2%) eye required a device replacement and 1 (1.2%) eye a device removal due to maculopathy. XEN63, either alone or in combination with phacoemulsification, significantly lowered IOP and reduced the number of ocular hypotensive medications. The rate of ocular hypotony was relatively high, although it was clinically relevant only in one eye.
Keywords: Bleb forming devices; Glaucoma; IOP; MIGS; Primary open-angle glaucoma; Subconjunctival MIGS.
© 2024. The Author(s).
Conflict of interest statement
José María Martínez-de-la-Casa has received funding as consultant from Allergan, Santen, Alcon, Pfizer, Novartis, Thea, B&L, Glaukos, AJL, and VISUfarma, research funding from Santen, Ivantis, Allergan, Pfizer, Glaukos, and Thea, and lecturer funding from Allergan, Santen, Alcon, Pfizer, Novartis, Thea, B&L, Glaukos, and ICare. Maria Teresa Marcos-Parra has received funding as consultant from AbbVie and Allergan. Elena Milla has received funding as consultant from AbbVie, Allergan, Santen, Brill, and Thea. Teresa Laborda has no interests to declare. Rafael Giménez Gómez has received funding as a lecturer from Abbvie, Santen and Brill. José Manuel Larrosa Carrera has received funding as consultant from AbbVie and Johnson&Johnson. Javier Aritz Urcola Carrera has received funding as consultant from AbbVie and Allergan. Miguel Ángel Teus has received funding as a lecturer from Alcon and funding as consultant from Allergan. Susana Perucho Martinez has received funding as a lecturer from AbbVie, Allergan, Visufarma and Thea.
Figures



Similar articles
-
Long-term effectiveness and safety of XEN45 in open-angle glaucoma patients.Int Ophthalmol. 2024 Jul 4;44(1):310. doi: 10.1007/s10792-024-03234-2. Int Ophthalmol. 2024. PMID: 38960998
-
Outcomes of XEN 63 Device at 18-Month Follow-Up in Glaucoma Patients: A Two-Center Retrospective Study.J Clin Med. 2022 Jun 30;11(13):3801. doi: 10.3390/jcm11133801. J Clin Med. 2022. PMID: 35807088 Free PMC article.
-
Effect of Preoperative Trabecular Meshwork Pigmentation and Other Eye Characteristics on Outcomes of Combined Phacoemulsification/Minimally Invasive Glaucoma Surgery.Ophthalmol Glaucoma. 2024 May-Jun;7(3):271-281. doi: 10.1016/j.ogla.2024.01.001. Epub 2024 Jan 6. Ophthalmol Glaucoma. 2024. PMID: 38185378
-
Ab interno trabecular bypass surgery with Trabectome for open-angle glaucoma.Cochrane Database Syst Rev. 2021 Feb 4;2(2):CD011693. doi: 10.1002/14651858.CD011693.pub3. Cochrane Database Syst Rev. 2021. PMID: 33580495 Free PMC article.
-
[XEN® Gel Stent for management of chronic open angle glaucoma: A review of the literature (French translation of the article)].J Fr Ophtalmol. 2019 Apr;42(4):391-403. doi: 10.1016/j.jfo.2018.10.005. Epub 2019 Mar 14. J Fr Ophtalmol. 2019. PMID: 30879831 Review. French.
Cited by
-
Efficacy and Safety of XEN63 Gel Stent Implant over 6 Months for Treatment of Glaucoma.J Clin Med. 2025 Apr 28;14(9):3036. doi: 10.3390/jcm14093036. J Clin Med. 2025. PMID: 40364068 Free PMC article.
-
Efficacy and Safety of Open-Conjunctiva Ab Externo 63 µm vs. 45 µm XEN® Gel Stent in Glaucoma Surgery: One-Year Follow-Up.J Clin Med. 2025 May 19;14(10):3545. doi: 10.3390/jcm14103545. J Clin Med. 2025. PMID: 40429540 Free PMC article.
-
Reducing Postoperative Needling in XEN63® Surgery with Adjunctive Cross-Linked Hyaluronic Acid Implant (Healaflow®): Early Evidence from Real-World Practice.J Clin Med. 2025 Aug 19;14(16):5848. doi: 10.3390/jcm14165848. J Clin Med. 2025. PMID: 40869674 Free PMC article.
-
Efficacy and Safety of Ab Externo Open Conjunctiva XEN® 63 µm Implantation with a 30G Needle Scleral Tract in Primary Open-Angle Glaucoma.J Clin Med. 2025 May 5;14(9):3195. doi: 10.3390/jcm14093195. J Clin Med. 2025. PMID: 40364226 Free PMC article.
-
Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma.Sci Rep. 2025 Jan 10;15(1):1634. doi: 10.1038/s41598-024-81616-3. Sci Rep. 2025. PMID: 39794378 Free PMC article.
References
-
- European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Azuara Blanco A., Traverso C.E. (eds). Br. J. Ophthalmol.105 (Suppl 1), 1–169 (2021) - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources